Torrent Pharmaceuticals share news and announcements
NSE: TORNTPHARMBSE: 500420Pharmaceuticals & BiotechnologyLarge Cap
Last close ₹4,524.40down ₹90.90 (1.97%)BSE ₹4,482.00
Share price at the NSE close on 23 Oct 2026. Previous close ₹4,615.30.
52-week range of traded prices to 23 Oct 2026
₹3,532.60Low, 6 Nov 2025₹5,250.00High, 3 Aug 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹1,72,094 Cr61st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 30 Jul 2026
- 78.9
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.84%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 30 Jul 2026
- 27.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 30 Jul 2026
- 11.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.84
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 3,28,59557.1% delivered
Torrent Pharmaceuticals board meetings
111 filed, newest first. Page 2 of 3.
Nov 2018
3 Nov · Board meeting
Oct 2018
Aug 2018
2 Aug · Board meeting
Jul 2018
May 2018
31 May · Board meeting
Jan 2018
25 Jan · Board meeting
Oct 2017
Jul 2017
May 2017
26 May · Board meeting
Jan 2017
Oct 2016
Jul 2016
May 2016
Mar 2016
Jan 2016
Oct 2015
Sep 2015
Jun 2015
Mar 2015
31 Mar · Board meeting
Inter alia, to consider the Audited Financial Results for the year ended on March 31, 2015.
Jan 2015
28 Jan · Board meeting
Dec 2014
Oct 2014
1 Oct · Board meeting
Inter alia, to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and half year ended on September 30, 2014. Further, as per the provisions of the Insider Trading Code of the Company, the trading window will remain closed between October 01, 2014 to November 06, 2014 (Board meeting for, inter alia, considering above results being held on November 05, 2014).
Jun 2014
30 Jun · Board meeting
Inter-alia, to consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for quarter ended June 30, 2014. Further the Company has informed that as per the provisions of the Insider Trading Code of the Company, the trading window will remain closed between July 01, 2014 to July 31, 2014 (Board meeting for, inter-alia, considering above results being held on July 30, 2014).
May 2014
12 May · Board meeting
Apr 2014
Jan 2014
Oct 2013
9 Oct · Board meeting
Inter alia, to consider & approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and half year ended on September 30, 2013.
Jul 2013
9 Jul · Board meeting
Inter alia, to consider & approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the Quarter ended June 30, 2013.
May 2013
14 May · Board meeting
To consider, inter alia, the Audited Financial Results of the Company for the year ended on March 31, 2013 and recommendation of dividend for the said year.
Jan 2013
17 Jan · Board meeting
To consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results ( with limited review ) on Consolidated basis of the Company for the quarter ended and nine months ended on December 31, 2012. In the meeting, Board would also consider payment of Interim Dividend for the year 2012-13.
Oct 2012
5 Oct · Board meeting
Inter alia, to consider & approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the second quarter and half year ended on September 30, 2012.
Jul 2012
3 Jul · Board meeting
Inter alia, to consider & approve the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the Quarter ended June 30, 2012.
May 2012
4 May · Board meeting
To consider, inter alia, the Audited Financial Results for the year ended March 31, 2012 and recommendation of final dividend for the said year.
Jan 2012
13 Jan · Board meeting
To consider and approve the Audited Financial Results on Standalone basis and Unaudited Financial Results ( with limited review ) on Consolidated basis of the Company for the quarter ended and nine months ended on December 31, 2011. In the meeting, Board would also consider payment of Interim Dividend for the year 2011-12.
Oct 2011
4 Oct · Board meeting
To consider, inter alia, the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and half year ended on September 30, 2011.
Jul 2011
15 Jul · Board meeting
To consider, inter alia, the Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis for the quarter ended June 30, 2011.
May 2011
12 May · Board meeting
To consider, inter alia, the Audited Financial Results of the Company for the year ended on March 31, 2011 and recommendation of dividend for the financial year 2010-11.
Jan 2011
4 Jan · Board meeting
To consider, inter alia, Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company as per Clause 41 of the Listing Agreement for the quarter and nine months ended on December 31, 2010.
Oct 2010
7 Oct · Board meeting
To consider, inter alia, Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company as per Clause 41 of the Listing Agreement for the quarter and half year ended on September 30, 2010.
Jul 2010
9 Jul · Board meeting
To consider, inter alia, Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter ended on June 30, 2010.
Apr 2010
20 Apr · Board meeting
To consider, inter alia, the Audited Financial Results of the Company for the year ended on March 31, 2010 and recommendation of dividend for the financial year 2009-10.
Jan 2010
13 Jan · Board meeting
To consider, inter alia, Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis as per clause 41 of the Listing Agreement for the quarter and nine months ended on December 31, 2009.
Oct 2009
16 Oct · Board meeting
To consider, inter alia, Audited Financial Results on Standalone basis and unaudited Financial Results (with limited review) on Consolidated basis as per clause 41 of the Listing Agreement for the quarter and half year ended on September 30, 2009.